NCT05591131Active, not recruiting
Genetic Testing in African Americans
Genetic Testing in African Americans Towards Universal Paired Tumor/Germline Genetic Testing in Solid Tumor Patients With Specific Gynecological Malignancies
Source: ClinicalTrials.gov · Last updated 21 Feb 2025
Brief summary (registry, in English)
This is a pilot/feasibility study to conduct genetic testing using tumor/blood samples of African American and Caucasian patients with ovarian and endometrial cancer following surgery at AU Health Medical Center. The aim of the pilot/feasibility study is to sequence a panel of cancer genes on paired tumor/blood (germline) samples of patients with ovarian and endometrial tumors at a two-week time point following surgery at AU Medical Center. While paired testing of tumor and blood (germline) provides direct clinical value to patients, investigators propose to study whether investigators can define and overcome such minority barriers among the Georgia Cancer Center (GCC)/AU Health Medical Center (AUMC) patient population.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 21 (actual)
- First submitted
- 19 Oct 2022
- Start date
- 20 Apr 2023
- Primary completion date
- Nov 2027
- Lead sponsor
- Augusta University
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT05591131
What you commit to
- Study type: Interventional
- Participants enrolled: 21
- From 20 Apr 2023 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are no exclusion criteria
- \-
Who the study is looking for
- Age ≥ 18 years of age.
- New diagnosis of ovarian, endometrial, fallopian, or primary peritoneal carcinoma.
- Diagnostic procedure performed at AU Health Medical Center.
- Adequate tissue is available for the tumor testing component (e.g., cytology and FNA samples are typically not adequate, whereas core biopsies and open biopsies usually are adequate.
- Consent at first post-biopsy outpatient clinic visit (typically about 2 weeks).
- Ability to provide informed consent in English.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Georgia Cancer Center at Augusta University Coordinator of this site? Confirm its status | Augusta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.